Wuxi, China – GenCefe Biotech is proud to announce that it has successfully obtained ISO 13485 certification, a globally recognized standard for quality management systems in the medical device and biotechnology industries. This milestone demonstrates the company’s unwavering commitment to delivering high-quality, reliable, and innovative solutions to its customers worldwide. 

ISO 13485 sets stringent criteria for the design, development, production, and delivery of medical-grade products. Achieving this certification underscores GenCefe Biotech’s dedication to excellence in its processes, ensuring that its solutions meet both regulatory and customer requirements. 

“This certification is a significant achievement for GenCefe Biotech and reflects our team’s relentless pursuit of quality and innovation,” said David Zheng, CEO of GenCefe Biotech. “It reinforces our position as a trusted partner in the biotechnology industry and enables us to better support our global customers with products and services that meet the highest international standards.” 

The certification also strengthens GenCefe Biotech’s ability to deliver specialized solutions in areas such as gene synthesis, RNA and DNA oligonucleotide synthesis, recombinant protein synthesis. By adhering to ISO 13485 standards, the company is well-positioned to expand its presence in regulated markets and further enhance customer satisfaction, and provide higher quality products and services to users around the world.

For more information about GenCefe and its offerings, please visit: 

www.gencefebio.com

For media inquiries or partnership opportunities, please

contact: [email protected]

Yi Du 

Marketing Director

GenCefe Biotech 

Email: [email protected]

Tel: +86 18626156521

About GenCefe Biotech:

GenCefe Biotech was established in Wuxi, China in 2020, and started its US branch in California in 2021. The company focuses on advanced technology development, large-scale production, and application of DNA, RNA, gene, and protein synthesis. We are committed to breaking through industry bottlenecks with advanced automation synthesis and artificial intelligence platforms and promoting the development of industries of synthetic biology, drug discovery and development, molecular diagnostics, etc.